Deep search
Rewards
Search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
My Bing
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Trending on Bing
Probe leads to resignation
Diagnosed with cancer
To speak at RNC convention
US forgives Indonesian debt
France to extradite US man
'Put his power up for sale'
Targets Trump immunity
Sequel in the works
Trump: Biden will stay in race
Receives military honors
Water advisory for MI city
$2B military loan for Poland
$6.8B grant for rail tunnels
Pay package lawsuit
Recalled for listeria risk
ND pot legalization efforts
New Jersey fines $100K
Turkey comm satellite launch
To meet new British PM
Trial jury selection process
Beryl claims 8 lives
US troops leave Niger
Settles antisemitism suit
Lead investigator suspended
'Candid Camera' star dies
Sentinel ICBM cost grows
$50M deal with UConn
Tire flies off during takeoff
2024 Washington summit
To hold rally in Florida
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Mounjaro, weight loss and Ozempic
Weight-loss drugs link to lower risk of obesity-related cancers
Blockbuster weight-loss and diabetes drugs may lower patients’ risk of developing some common types of cancer that are closely linked to obesity, new evidence suggests.
Weight Loss Medications Linked To Lower Cancer Risk, According To Study
GLP-1 drugs, like Ozempic and Wegovy have been associated with a lower risk of cancer in diabetics according to a new study.
Ozempic and Related Drugs May Reduce Cancer Risks, Study Claims
GLP-1 drugs like Ozempic may lower obesity-related cancer risks, although no direct correlation has been confirmed.
Healthline
3d
GLP-1 Drugs Like Ozempic May Reduce Risk of These 10 Cancers
Share on Pinterest A study finds that people with type 2 diabetes who took semaglutide were less likely to develop certain ...
The American Journal of Managed Care
3d
GLP-1 Agonists May Reduce Cancer Risk for Patients With Diabetes
Among patients with type 2 diabetes, glucagon-like peptide 1 (GLP-1) receptor agonists reduced their risk of obesity-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback